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ABSTRACT

Gliomas represent approximately 80% of all malignant brain tumors, and
glioblastoma multiforme (GBM) accounts for nearly half of all gliomas. GBM is the most
common and aggressive primary brain tumor. Despite aggressive treatment including
tumor resection followed by radiation and chemotherapy, the median survival rate for GBM
averages between 12 and 15 months, with a 2-year survival rate less than 25%. Therefore,
new therapeutic strategies are needed to improve the survival rate of those affected by
GBM. Chemotherapy with the DNA alkylating agent, Temozolomide (TMZ), is commonly
used as a first-line treatment for GBM. TMZ is an orally delivered drug that is known to be
stable or inactive in the acidic pH environment of the stomach and begins to convert to its
active form at a neutral pH in the bloodstream. However, studies have shown that full
conversion of TMZ to its active form occurs at a more basic pH. Further, after TMZ is
converted to its active form, it is unable to cross the blood-brain barrier, thereby limiting
availability in the brain and lowering the effectiveness of TMZ.

Recently, peptides have been utilized as delivery systems for hydrophobic
anticancer drugs or agents. These peptides are advantageous due to their
biocompatibility, and high loading capacity for hydrophilic and hydrophobic drugs. To
facilitate the delivery of TMZ, and potentially other hydrophobic drugs, we propose an
innovative local delivery strategy using hydrophilic and alternating hydrophobic and acidic
amino acids to form a peptide hydrogel. We hypothesize that the hydrophobic residues of
the peptide hydrogel will load TMZ, and the hydrophilic residues will convert TMZ to its
active form as the hydrogel degrades. This therapeutic strategy will allow for extended
release of TMZ, thus increasing the efficacy of the drug.
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In this study, peptide sequences were designed, synthesized, and formed into
hydrogels for the delivery of TMZ. In vitro experiments validated that TMZ dissolved at a
higher pH resulted in significantly increased cytotoxicity in LN-18 and T98G human
glioblastoma cells. We also demonstrated that at various concentrations, the proposed
peptide hydrogel efficiently loads TMZ and the release profiles can be adjusted based on
peptide composition. Further, studies showed that TMZ-loaded peptide hydrogels
mediated greater anticancer activity in LN-18 cells compared to delivery of TMZ alone.
Overall, our results demonstrate the therapeutic potential of the TMZ-loaded peptide
hydrogels for local drug delivery in treating GBM.
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CHAPTER 1
INTRODUCTION & BACKGROUND

Each year an estimated over 25,000 adults and children in the United States will
be diagnosed with cancerous tumors in the brain or spinal cord.1 The frequency of brain
tumors increases with age, with the median age of diagnosis being 59,1 and an average
incidence of 40.1 per 100,000 in those over 40.1 Brain tumors are also the most common
cancer in children between the age of 0-14, and the third most common cancer-related
death in people between the ages 15 and 39.1
Of the many types of central nervous system and primary brain tumors, gliomas
and meningiomas are the most common.2 Gliomas represent 24.7% of all primary brain
tumors and other CNS tumors and 74.6% of malignant brain tumors.2 Gliomas are
known to arise from supporting cells of the brain, such as astrocytes or
oligodendrocytes, and are classified based on the malignancy grade. Grade I tumors are
benign with an almost normal appearance, grade II is considered low-grade diffuse
glioma, grade III is classified as malignant diffuse glioma, and grade IV is considered
glioblastoma.2 The grades are assigned based on the presence/absence of necrosis,
amount of proliferation, and mitotic activity.2 Glioblastoma multiforme (GBM) is the most
common malignant brain tumor with an incidence of 5-8 people per 100,000, and overall
accounting for 55.4% of gliomas1. With a median age of onset at 64, GBM follows the
same trend as all cancerous brain tumors; the incidence rate increases with age, with
the highest diagnoses rates occurring between ages 75-84 years old. The incidence of
GBM is slightly higher in men than in women, and occurs more often in Caucasians
compared to other ethnicities.3 The median survival rate for patients with GBM is
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between 12 to 15 months,4 even with aggressive treatment involving surgery,
chemotherapy, and radiation.4
1.1 Current Treatment
The current standard of care for treating GBM includes maximal surgical resection,
followed by radiation, and then chemotherapy.3 However, complete resection of GBM
tumors is difficult due to the invasive nature of the tumors and the areas of the brain in
which they are located, which are usually responsible for controlling speech and motor
function.3 The current standard treatment following surgical resection consists of
radiotherapy plus concomitant chemotherapy with temozolomide (TMZ).3 TMZ is a
prodrug that undergoes spontaneous hydrolysis at physiological pH to the active
metabolite 3-methyl-(triazen-1-yl)imidazole-4-car-boxamide (MTIC).5 The drug further
hydrolyzes into 5-amino-imidazole-4-carboxamide (AIC), providing the active alkylating
or reactive portion of the drug needed to promote DNA methylation.5 TMZ primarily
exerts its affect by methylation of guanine DNA at the O6 position, initiating a base pair
mismatch, and ultimately leading to apoptosis.5 TMZ was approved for treatment of
glioblastoma in 1999, and has a 96-100% bioavailability when delivered orally.6 Due to
the pharmacokinetic properties of TMZ, only 30% of the drug has been found to reach
the central nervous system.7 Despite this, studies have shown that patients receiving
radiation therapy along with concomitant and adjuvant TMZ treatment was more
effective than radiation alone.4 In one study, patients who received radiotherapy with
TMZ had a median survival time of 14.6 months with a two-year survival rate of 27.2%,
compared to 12.1 months and 10.9% of patients surviving two years that received
radiotherapy alone.4 Since GBM is a highly vascularized tumor and is characterized by
increased endothelial growth factor signaling, utilizing antiangiogenic therapeutic
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strategies in addition to TMZ have been explored.6 Bevacizumab is a monoclonal
antibody antiangiogenic therapy that was approved in 2009 for treatment of GBM.
Bevacizumab binding to vascular endothelial growth factor (VEGF) prevents interaction
with the VEGF receptor, resulting in a reduction of vascular growth within the tumor.8
Clinical trials testing the combination of bevacizumab with TMZ and radiotherapy have
reported improvement of progression-free survival in patients with GBM, but no gain in
overall survival.9
In addition, local delivery of an alkylating drug, bis-chloroethylnitrosourea (BCNU),
has been explored using Gliadel wafers, a polymeric (poly carboxyphenoxypropane/sebacic acid anhydride) substrate that allows release of BCNU for
approximately 3 weeks.6 Locally administered gliadel wafers allow for a reduction in
systemic toxicity and a higher drug concentration at the tumor resection site.10 Gliadel
wafers have been used as an adjuvant therapy in combination with systemic delivery of
temozolomide, but the adjuvant therapy effectiveness was limited due to toxicity and
small survival increase.6

1.2 Barriers to Current Treatment
Several barriers remain for providing effective drug treatment to patients with GBM;
these include crossing the blood-brain barrier (BBB) and development of
chemotherapeutic resistance.

1.2.1

Blood Brain Barrier
The blood-brain barrier (BBB) is composed of brain endothelial cells with tight

junctions that allow diffusion of water and small lipophilic molecules, but prevent the
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passage of large, charged, or potentially dangerous molecules.11,12 This limitation
creates a challenge for drug treatment of brain tumors, like GBM. Drug delivery to the
brain is most commonly performed by using either a pharmacological or neurosurgicalbased approach.13 The pharmacological-based approaches use various drug
conjugations or drug delivery platforms such as self-assembling peptides,14 liposomes,15
or polymeric drug carriers.15 The pharmacological-based approach uses invasive
methods that involve intraventricular infusion, intracerebral delivery, and convectionenhanced diffusion.12
A common way to improve the delivery of a brain cancer drug is through drug
lyophilization or conversion of the drug into a lipophilic molecule. Prodrugs for delivery
across the BBB are formed by linking nonpolar groups to the active molecule,11 allowing
concealment of the polar groups in the active drug, therefore transforming a watersoluble drug into a lipid-soluble prodrug.11 The prodrug is then able to cross the BBB and
is converted to the active drug. Furthermore, if the active drug is polar, exit from the
brain into the systemic circulation will be hindered.16 Conjugation of drugs, by either
addition of a nonpolar group or molecular alteration, to form prodrugs are popular due to
their enhanced BBB permeability.

1.2.2

Chemotherapeutic Resistance
Glioblastoma has been found to have either intrinsic or acquired resistance to

chemotherapy. Acquired drug resistance to chemotherapeutic prodrugs, like
temozolomide, has been attributed to the (O)6-methylguanine-DNA-methyltransferase
(MGMT) gene. MGMT is a DNA repair protein that functions by removing alkyl groups
from the O6 position of guanine, correcting drug-induced DNA damage and preventing
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apoptosis.6 Therefore, when TMZ and other alkylating agents are used for therapy, they
encounter resistance due to upregulation of MGMT. Since alkylating agents exert
therapeutic effects by generating DNA damage, the MGMT status of a patient is strongly
correlated with chemotherapeutic resistance, and as a result, the efficacy of treatment
when using alkylating drugs.17 Methylation or lower expression of MGMT has been
associated with an increase in positive outcomes when treating patients with
glioblastoma with TMZ.17
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CHAPTER 2

RELEASE APPROACHES AND ACTIVATION STRATEGIES FOR PRODRUGS

2.1 Introduction to Prodrugs
Prodrugs are used extensively in the delivery of cytotoxic compounds to cancer
cells. The development of successful therapies for cancer treatment is increasingly
challenging due to the barriers that diminish drug efficacy. These difficulties potentially
affect the drug bioavailability, solubility, and distribution. Consequently, further significant
issues may arise, such as adverse side effects, shorter drug duration, and reduced drug
stability.18 In order to overcome these barriers, the use of prodrugs has become an
effective tool in cancer therapies.
The term prodrug, introduced by Adrien Albert in 1951, refers to a reversible
molecule with desirable drug properties, which does not possess any pharmacological
effects until conversion to its active form.19 The aim behind prodrug design is to mask
undesirable properties of therapeutics, such as poor water solubility or chemical
instability.20 This mask allows prodrugs to remain in their inactive form until enzymatic or
chemical transformation initiates release of the active form of the drug.20 The justification
behind the use of prodrugs is to improve the overall bioavailability, biodistribution,
metabolism, excretion, and undesirable toxic effects of the parent drug (or adsorption,
distribution, metabolism, excretion and toxic properties).20 These properties remain
muted until the prodrug reaches the targeted tumor or intended site of action.
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(A)

Barrier

(B)

Figure 1.1 Schematic representation of the prodrug concept. (A) Carrier-linked prodrug allow improved
pharmacokinetics of the drug. The carrier-linked portion of the prodrug indicates the part of the prodrug that is
pharmacologically inactive. The barrier represents the limitations of the parent drug that prevent optimal
pharmacokinetic performance. (B) Carrier-linked prodrugs are activated through enzymatic or non-enzymatic
cleavage of the drug from the carrier (adapted from Rautio et al. 2008).

18

There are two main classes of prodrugs: carrier-linked prodrugs and bioprecursor
prodrugs. In carrier-linked prodrugs, the drug is linked to a moiety (or temporary carrier)
through a bioreversible covalent linkage.21 This carrier generally improves the
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pharmacokinetics of the drug due to its lipophilic nature, allowing it to overcome barriers
to optimal pharmacokinetic performance (Fig. 1.1A). To release the parent drug or
activate the prodrug, the carrier can be easily removed in vivo through enzymatic and/or
non-enzymatic cleavage22 (Fig. 1.1B). Bioprecursor prodrugs result from molecular
alteration of the active drug itself. This modification allows the prodrug to be converted
metabolically or chemically to its active compound.
Prodrugs are commonly activated in two ways: actively, via enzyme hydrolysis,
or passively, via reduced pH or hypoxia. Our aim is to present an overview of the two
prodrug activating strategies. Specifically, we will highlight the common approaches to
converting prodrugs to their active form.

2.2 Active Targeting: Enzyme responsive therapies
Anticancer prodrugs can be designed to target certain molecules, such as
enzymes and antigens, which are commonly overexpressed in tumor cells.23 Enzyme
Prodrug Therapy (EPT) is widely-used as a method for converting cancer prodrugs into
active drugs through hydrolysis in the body. The principal technique of EPT is to deliver
a drug-activating enzyme to cancerous tissues and then systemically dispense the
prodrug.23 This method allows local activation of the prodrug, which is essential in
preventing systemic adverse side effects.
Activation of prodrugs in tumor tissues by enzymes can be achieved in two ways:
antibody-directed enzyme prodrug therapy (ADEPT), and gene-directed enzyme prodrug
therapy (GDEPT)23. Here we discuss strategies for active transformation of prodrugs
using enzymatic therapies in detail as well as their benefits and limitations.
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2.2.1 Antibody directed enzyme prodrug therapy (ADEPT)
Antibody directed enzyme prodrug therapy (ADEPT) was first proposed almost
30 years ago to overcome the restrictions of early antibody directed cancer therapy.24
ADEPT is a strategy that uses a drug-activated enzyme attached to a tumor-related
antibody. After the prodrug is systemically administered, the enzyme located on the
tumor site will convert the prodrug to its active form. This results in localized cytotoxic
effects to the tumor due to the targeting of the tumor-related antibody.25 Limitations of
the ADEPT system include immunogenicity of the antibody, inefficient delivery of
antibody and enzyme to all tumor cells, and difficulty of producing large amounts of
active drug, resulting in low levels of cytotoxicity.26

2.2.2 Gene-directed enzyme prodrug therapy (GDEPT)
Gene-directed enzyme prodrug therapy (GDEPT), also known as viral directed
enzyme prodrug therapy (VDEPT) or suicide gene therapy, utilizes a viral vector to
deliver a gene encoding an enzyme that will convert a prodrug into its active, lethal form
within a tumor.27 Upon production of the desired enzyme, the systemically delivered
prodrug can then be activated.27 Common viruses used in GDEPT are adeno-associated
viruses (AAV), retroviruses, herpes simplex virus (HSV), and Epstein-Barr virus (EBV).25
Enzymes commonly delivered include thymidine kinase,28 cytosine deaminase,29 and
cytochrome P450.30 Despite the high delivery efficiency, there are several limitations to
using viral vectors that still remain. There is a slight risk of the virus reverting to its wildtype form, causing mutations in the genome.31 Also, most retroviral vectors can only
integrate into dividing cells, which even in high-grade invasive tumors only represents
approximately 11.2-23.4% of tumor cells.32 This excludes the type of retroviral vector
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known as lentiviruses, which are able to infect both proliferating and non-proliferating
cells.33 Despite this, the majority of tumor cells would not be targeted using retroviruses.

2.3 Common Enzyme/Prodrug Systems
2.3.1 Carboxypeptidase G2 (CPG2)/Nitrogen mustard
The enzyme carboxypeptidase G2 (CPG2) is derived from the Pseudomonas
strain RS-16.34 CPG2 works by cleaving glutamic acid from nitrogen mustard-based
drugs creating DNA-alkylating agents with the capacity to methylate DNA.34 The
activated drug then has the ability to cause DNA cross-linking, which leads to
apoptosis.35 CPG2 also possesses the ability to diffuse through cell membranes without
the need for gap junctions, demonstrating versatility compared to other enzymes.35
Using CPG2 in enzyme-prodrug chemotherapy is effective, but this strategy is hindered
by the enzymes’ off-site targeting of the prodrug.36 Currently, studies are being
conducted to create an inhibited version of the enzyme that can be regulated through
proteolysis by a tumor-specific protease,36 allowing an increase in the localization effects
of the prodrug and a decrease in off-site targeting. A study conducted by Yachnin et al.
showed that it is possible to generate a protease-regulatory form of CPG2, which will be
valuable in upcoming enzyme-prodrug therapy.36

2.3.2 Herpes Simplex Virus-Thymidine Kinase (HSV-TK)/Ganciclovir
In the Herpes Simplex Virus-Thymidine Kinase (HSV-TK) system, ganciclovir
(GCV) is phosphorylated by the thymidine kinase enzyme.35 Following phosphorylation,
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the triphosphate form of GCV is produced.35 This GCV triphosphate form can then cause
apoptosis in tumor cells by introducing single-stranded breaks into DNA. Unfortunately,
GCV can only affect dividing cells, and it has limited transportation capacity because gap
junctions are required for transport.35 There are also risks in using a viral system, such
as triggering the immune system, mutations, and restricted migration.35 Recently,
Hashemi et al. demonstrated in a GBM disease model that the HSV-TK system could be
improved by incorporating olfactory ensheathing cells (OECs).37 These cells are
removed from human olfactory mucosa and have the ability to migrate toward
astrocytes.37 The cells then can deliver the HSV-TK gene to tumorigenic astrocytes,
inducing cell death. Another study conducted by Wu et al. showed that transfer of GCV
could be increased by improving a study that used an approach combining two GDEPT
systems.38 Cell were retrovirally transduced with cytosine deaminase-uracil
phosphoribosyltransferase and HSV-TK.38 The result of the combination was inhibited
growth and high therapeutic efficacy in lung metastases.31 Other approaches examined
the use of valacyclovir, the prodrug form of acyclovir, instead of GCV, and higher
efficacy was observed.27,35

2.3.3 Cytosine Deaminase (CD)/5-Fluorocytosine
In the cytosine deaminase (CD) system, 5-fluorocytosine (5-FC), an antifungal
prodrug, is converted to its active form, 5-fluorouracil (5-FU), by the enzyme CD.25 After
conversion, active 5-FU is effective in killing tumor cells but causes side effects, such as
dermatitis, cardiac toxicity, and mucositis.35 Despite this, 5-FU has the ability to travel
independently of gap junctions by diffusion, unlike HSV-TK. This feature of 5-FU allows
the prodrug to induce more cell death than most systems. CD/5-FC has been utilized for
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treating various types of cancer, including colon,39 liver,39 breast,40 glioma,41 and ovarian
cancer.29,42 To overcome the weaknesses of CD/5-FC, groups have worked to address
off-targeting, optimizing the prodrug, and optimizing delivery capacity. Takahashi et al.
demonstrated that CD/5-FC increases cytotoxic effects in glioma cells in response to the
radiosensitizing effect of 5-FU.43 Another study combined CD/5-FC with a nonlytic
retroviral replicating vector (TOCA 511), where TOCA 511 acts as a carrier for cytosine
deaminase (CD). Ostertag et al. proved that TOCA 511 was capable of effectively
delivering and activating the prodrug, which resulted in tumor shrinkage and growth
inhibition.44

2.3.4 Cytochrome P450 (CYP)/Oxazaphosphorines
One third of all P450 enzymes are involved in activating anticancer prodrugs.30
P450 enzyme concentrations differ in various areas of the body, so the P450 enzymes
may be manipulated to target select tissues or areas for drug activation.30 Anticancer
prodrugs involved with P450 enzymes are oxazaphosphorines, which include
Cyclophosphamide (CPA) and Ifosfamide (IFA). These alkylating prodrugs are
substrates that the P450 enzyme metabolizes to yield a 4-hydroxy derivative product,
the active form of the prodrugs.35 The yielded product forms DNA cross-links that
ultimately lead to cell death. Similar to 5-FU, the resulting active prodrug from CPA/IFA
can be transported independently of gap junctions,35 which provides the system with a
higher level of potency than others. Another advantage of the CYP system is the
decrease in immunogenicity due to P450 enzymes already existing in the human body.35
Lack of specificity is a major weakness of the system because P450 liver enzymes
metabolize prodrugs, generating active metabolites throughout the entire body instead of
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in one specific location. This causes serious side effects, including neurotoxicity,
cardiotoxicity, and nephrotoxicity.35 However, a few approaches have been used to
reduce systemic toxicity. In one approach, encapsulated cells overexpressing the CYP
enzyme were implanted around malignant mammary tumors, and the patients were
given CPA following implantation. The results showed no adverse systemic side
effects.45 Despite these promising results, there are still fears about using the CYP
system due to the systemic activation of CYP450 in humans.

2.3.5 Summary
There has been significant progress in the development of enzyme/prodrug
systems. Developing safe vectors and enzymes to achieve local drug delivery and
prevent off-target effects remains the focus of current research. Efforts are being made
to move away from traditional prodrug activation methods due to their instability and
other drawbacks mentioned previously. For example, Du et al. has developed metalcontained enzyme mimics (MEMs) for prodrug activation. These MEMs can copy the
functions of natural enzymes and be used for prodrug activation.46 Overcoming these
issues may increase the possibility of eradicating incurable and hard to treat cancers.

2.4 Passive Targeting: Environment Responsive Therapies
Unlike active targeting, which utilizes enzymes or antigens, passive targeting
exploits the pathophysiological abnormalities that result from malignant tissue.47 These
abnormalities include the hypoxic environment of tumor tissue and the difference in
intracellular pH. These changes can be manipulated beneficially by designing prodrugs
that will selectively activate in these tumor environments. Here we discuss common pHresponsive linkages and hypoxia-activated prodrugs (HAPs).
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2.4.1 pH Responsive
The intracellular pH within solid tumors is maintained near a pH range of 5.7-7.6
due to the buildup of acid metabolites resulting from an imbalance of metabolic rates,
glucose consumption rates, and proton transport.48 Therapeutic strategies have been
designed to exploit tumor pH by using prodrugs which activate at low pH. pH-responsive
prodrugs can be attained through drug conjugation to cleavable acid-linkages. Common
pH-responsive linkages include acetals, anhydrides, and hydrazones.49 These linkages
are bonded to the drug, rendering it inactive or in prodrug form, until the chemical bonds
are cleaved at a low pH to allow drug hydrolysis.50 Hydrazone linkages have
demonstrated fast hydrolytic cleavage at a low pH compared to a neutral physiological
pH.50 Alendronate-monoethyl adipate-hydrazone (ALN-MA-hyd) has been used as a
linker for doxorubicin (DOX) to deliver the chemotherapeutic to bone tumor tissue.51 The
conjugate released DOX at a pH of 5, and also proved to be relatively stable at
physiological pH.52 In another study, a hydrazone bond was used to conjugate DOX to a
di-block copolymer composed of poly(L-lactic acid) (PLLA) and methoxy-poly(ethylene
glycol) (mPEG).51 The study showed that in an acidic environment of pH 3 or 5, most of
the DOX was cleaved from the hydrazone linkage, allowing for DOX to hydrolyze and
mediate cell death. At a pH of 7, the amount of DOX released was less than 10%, which
confirmed that the encapsulated DOX remained stable at neutral pH.51 The DOXconjugated polymer allowed for increased drug uptake in lymphoblast cells at a low pH
and slower release of DOX at a physiological pH.51

2.4.2 Hypoxia Responsive
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The environment within most tumors contains areas of hypoxia due to poor blood
supply, or a state of low oxygen, which is known to promote tumor resistance to
chemotherapy and radiotherapy.53 Oxygen is a radiosensitizer, a molecule that facilitates
oxidation of free radicals in DNA during tissue irradiation.54 Thus, hypoxic tumor cells are
resistant to radiotherapy. The hypoxic tumor cells are also resistant to most
chemotherapies, due to the tumor cells being quiescent and chemotherapeutic drugs
only targeting proliferating cells.53 Chemotherapy and radiotherapy resistance is also
often due to the development of an aggressive phenotype that promotes resistance to
apoptosis, inhibition of DNA repair, increased angiogenesis, metastasis, and an
abundance of other effects.53 Thus, the therapeutic strategy of hypoxia-activated
prodrugs (HAPs) was developed to target hypoxic tumors.
PR104 is a nitroaromatic compound, a water-soluble phosphate ester, which
upon activation, quickly hydrolyzes in a hypoxic environment into an alcohol, PR104A.55
PR104A is then metabolized by oxidoreductases in the body, which results in DNA
cross-linking or cell death.53,55 Studies have shown that PR104 could be used to
eradicate acute myeloid leukemia and acute lymphoblastic leukemia.55 Patients with
these diseases are known to exhibit high levels of hypoxia at their tumor sites.55 In a
phase I/II study, PR104 was given to patients with refractory or relapsed acute myeloid
leukemia or acute lymphoblastic leukemia. The patients were administered an
intravenous infusion of PR104 every 14-28 days for up to 3 cycles. Overall, the study
demonstrated PR104 effectiveness, but due to the toxicity of PR104, it is unlikely to be
successful long-term.55
TH-302 is a hypoxia-activated prodrug of bromo-isophosphoramide. Reduction of
the nitrogen group on TH-302 causes the prodrug to release a DNA-crosslinking
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alkylating agent in hypoxic regions.53 Studies have shown that TH-302 can be utilized for
a broad range of applications, but is most commonly used to treat myeloma. In one
study, TH-302 was used to target hypoxic bone marrow niches in leukemia and the
results showed that leukemia cells were reduced when treated with TH-302.56 The study
also showed that using TH-302 followed by chemotherapy increased survival in mice.56
Despite in vivo success, phase III clinical trials did not show effective results.56 This was
due to side effects, such as myelosuppression. TH-302 is selective by only affecting
hypoxic areas and shows potential for targeted therapy in cancer treatment.

2.4.3 Conclusion
One of the key advantages of pH-responsive prodrugs is that they are able to
exploit tumor tissue pH for activation. These pH-responsive prodrugs allow efficient
delivery at the tumor site and minimization of harmful off-target side effects. Despite this,
pH-responsive delivery systems have not performed well in clinical studies for cancer
therapy. This is due to ineffective translation of the in vitro properties to in vivo studies.57
Hypoxia-activated prodrugs are useful for targeting hypoxic tumors. These
tumors are known for being difficult to treat, and this particular strategy offers an
advantage for treating aggressively resistant tumor types. However, the therapeutic
benefit of hypoxia-activated prodrugs is currently limited. The toxicity associated with the
use of the hypoxia-activated prodrugs, along with the lack of prodrug optimization,
reduces the clinical potential of this strategy.

2.5 Conclusion/Final Remarks
Bioengineering strategies have been explored to improve the release or
activation of prodrugs through active or passive activation methods. Active targeting
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methods that involve enzyme/prodrug systems are effective but include many unsafe
delivery vectors and enzymes. Passive targeting methods, which rely on environment
activation, allow for more efficient, local delivery, and in turn a reduction of harmful side
effects. Despite this, passive targeting systems still lack effective translation to in vivo
studies. The future of prodrug therapy for both targeting methods begins with the
development of safer delivery systems, along with prodrug optimization for effective
translation to clinical trials.
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CHAPTER 3

RESEARCH AIMS

3.1 Objectives
Gliomas represent approximately 80% of all malignant brain tumors, and
glioblastoma multiforme (GBM) accounts for nearly half of all gliomas.1 GBM is the most
common and aggressive primary brain tumor. Despite aggressive treatment including
tumor resection followed by radiation and chemotherapy, the median survival rate for
GBM is 15 months.2 Therefore, new therapeutic strategies are needed to improve the
survival rate of those affected by GBM.
The objective of this research is to target GBM by developing a local anticancer
drug delivery system using peptides, that will self-assemble in water to form a hydrogel.
Chemotherapy with the DNA alkylating agent, Temozolomide (TMZ), is used as a firstline treatment for GBM. Studies have shown that full conversion of TMZ to its active form
occurs at a more basic pH (pH>7.5).5 Furthermore, after TMZ is converted to its active
form, it is unable to cross the blood brain barrier, thereby limiting availability in the brain
and lowering the effectiveness of TMZ. Therefore, my central hypothesis and the overall
goal of this research is to develop an innovative local delivery strategy using hydrophilic
and alternating hydrophobic and acidic amino acids to form a hydrogel that will
encapsulate TMZ and convert the drug to its active form.
By pursuing the following aims, I will gather the data essential to develop a
delivery system that will improve the efficacy of TMZ and extend the survival rate for
patients with GBM. The study aims are listed and discussed below.
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Aim 1: Determine whether the peptide compositions/designs will allow for loading
of the anticancer prodrug. To accomplish this aim, we will design, synthesize, and test
the ability of three different peptides to load TMZ. These peptides will differ in number of
hydrophobic and hydrophilic sites. Based on this and the hydrophobic nature of TMZ, we
hypothesize that the peptides will be able to load TMZ. We also believe that increasing
the number of hydrophobic amino acids will allow for loading of more TMZ.
Aim 2: Characterize the structural properties of peptide hydrogels. We will
determine the sizing, zeta potential, formation of secondary structures, and release
profile of each peptide hydrogel. We hypothesize that the release of drug from each
peptide will be associated with the ratio of hydrophobic to hydrophilic amino acids. We
also hypothesize that sizing of each peptide hydrogel will be relatively similar, there will
be formation of secondary structures, and the zeta potential will correlate with the
amount of charged amino acids of each peptide.
Aim 3: Assess drug release from the loaded peptide hydrogels. To accomplish this
aim, we will load a dye into the hydrogels and measure the change in fluorescence over
time. We hypothesize that dye release will be slower in the peptide hydrogel that
consists of more hydrophobic amino acids, and faster in the peptide hydrogels with less
hydrophobic residues.
Aim 4: Determine the cell viability of human glioblastoma cells treated with the
TMZ-loaded peptide hydrogel compared to TMZ delivered alone. Each peptidehydrogel loaded with TMZ will be delivered onto LN-18 cells and assessed for an
increase in cytotoxicity. We hypothesize that increased conversion of TMZ into its active
form will be based on the number of basic amino acids in each peptide.
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3.2 Approach
Aim 1:
We will first evaluate whether TMZ is more active/cytotoxic when dissolved in a
basic pH environment and delivered onto human glioblastoma (LN-18 and T98G) cells.
This will be performed to determine whether our peptide designs will potentially be
effective in conversion of TMZ into its active form.
Aim 2:
Once the appropriate peptide compositions have been chosen, the peptide
hydrogels will be characterized using circular dichroism (CD) for secondary structure
analysis, zeta potential for structure stability, and dynamic light scattering to measure
particle size. After the assessment of TMZ in a basic environment, and characterization
of the peptide hydrogels, the amount of TMZ loaded will be assessed. TMZ will be
loaded into the peptide hydrogels at 3 peptide concentrations (0.05, 0.1, and 0.5 mg/mL)
and a TMZ concentration of 200 µM. The amount of loaded TMZ will be determined by
high-performance liquid chromatography (HPLC).
Aim 3:
Based on the TMZ loading results, the peptide concentration that exhibited the
maximum amount of loading will be selected for the release and cytotoxicity study. To
study release, phenol red will be loaded into each peptide hydrogel. The peptide
hydrogels will then be incubated at 37°C. The absorbance of phenol red will be taken at
several time points to determine the amount released over time.
Aim 4:
Lastly, the cytotoxicity of the TMZ-loaded peptide hydrogels in human
glioblastoma (LN-18) cells will be evaluated by MTT assay.

20

CHAPTER 4
IMPLANTABLE SELF-ASSEMBLING PEPTIDE-HYDROGEL DRUG DELIVERY
SYSTEM FOR TREATING GLIOBLASTOMA MULTIFORME
Temozolomide (TMZ) has been used for anticancer treatment since its approval
in 1999.6 TMZ is a slightly hydrophobic prodrug, that is able to exert its anticancer
effects by methylation of purine bases of DNA, including O6-guanine, N7-guanine, and
N3-adenine, initiating base pair mismatches.7,58 TMZ is delivered orally and known to
remain stable in its native form in the acidic environment of the stomach. The drug is
absorbed in the bloodstream and begins to convert into its active form, known as 5-(3methyltriazel-1-yl)-imidazo-4-carboxamide (MTIC), at a neutral or physiological pH.5
However, studies have shown that full conversion of TMZ into its active form occurs at a
more basic pH (>7.4),5 suggesting that the therapeutic effect of TMZ is limited. Further,
TMZ is the standard-of-care chemotherapy drug for treating patients with glioblastoma,
but the median survival rate remains low at 14.6 months with aggressive treatment.6
Development of carriers tailored to the mechanism activating TMZ have not been
previously explored but may enhance the effectiveness of the drug.
Peptides that are able to self-assemble into different nanostructures are very
attractive for biomedical applications such as drug delivery. These self-assembling
peptides are advantageous due to their biocompatibility and high loading capacity for
hydrophilic and hydrophobic drugs.59 These peptides are able to self-assemble due to
hydrogen bonding, hydrophobic interactions, and electrostatic interactions that combine
and form stable nanostructures.60 Among these self-assembling peptides is a class of
peptides that are able to self-assemble into hydrogels when introduced to water. This is
due to the alternating hydrophilic and hydrophobic nature of the amino acids.61 Recently,
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self-assembling peptides have been utilized as local delivery systems for protein drugs
and hydrophobic anticancer drugs or agents.61 To facilitate the delivery of TMZ, and
potentially other hydrophobic prodrugs, we developed a novel peptide hydrogel delivery
system.
The peptides were designed and consisted of basic and alternating hydrophobic
and acidic amino acids. We demonstrated that at various concentrations, the peptide
hydrogels are able to efficiently load TMZ, and the release profiles can be adjusted
based on peptide composition. In vitro experiments confirmed that TMZ dissolved at a
higher pH resulted in significantly increased cytotoxicity in LN-18 and T98G human
glioblastoma cells. Studies also showed that TMZ-loaded peptide hydrogels exhibited
greater anticancer activity in LN-18 cells compared to delivery of TMZ alone.

4.1 MATERIALS AND METHODS

4.1.1 Materials
Peptides AE12K4 (AEAEAEAEAEAEKKKK-), AE8K8 (AEAEAEAEKKKKKKKK),
and AE4K12 (AEAEKKKKKKKKKKKK) were synthesized and purified (purity >95%) by
GenScript USA Inc (Piscataway, NJ). The N and C terminals of the peptides were
protected by acetyl and amino groups, respectively. TMZ (³98% pure), Phenol Red, and
Thiazolyl Blue Tetrazolium Bromide (TBTB) were purchased from Sigma-Aldrich (St.
Louis, MO). The LN-18 and T98G human glioblastoma cell lines were obtained from
ATCC (Manassas, VA). The LIVE/DEAD Viability/Cytotoxicity Kit as well as cell culture
reagents, including fetal bovine serum (FBS), penicillin-streptomycin, and trypsin were
acquired from ThermoFisher Scientific (Waltham, MA). Cell culture medium DMEM,
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EMEM, and Methanol (³99% pure) were obtained from VWR (Radnor, PA). pH buffers
were obtained from ThermoFisher Scientific.

4.1.2 Cell Culture
The human glioblastoma cell line LN-18 was cultured in Dulbecco’s Modified
Eagle Medium (DMEM) with 10% fetal bovine serum (FBS), and 1% antibiotic (100iU/mL
penicillin/100ug/mL streptomycin). The human glioblastoma cell line T98G was cultured
in Eagle’s Minimum Essential Medium (EMEM) with 10% fetal bovine serum (FBS), and
1% antibiotic (100IU/mL penicillin and 100ug/mL streptomycin). Both cell lines were
grown in an incubator at 37°C with 5% CO2.

4.1.3 Cytotoxicity of TMZ at various pH
To determine whether the anticancer activity of TMZ is pH dependent,
cytotoxicity of TMZ on glioblastoma cells was examined in various pH environments. LN18 or T98G cells were plated at 1X105 or 0.9X105 cells per well in 24-well plates and
allowed to attach overnight. TMZ was dissolved in water at a pH of 2.5, 7.5, and 12. TMZ
from each pH environment was added to LN-18 and T98G cells for a final concentration
of 200 µM and allowed to incubate in media containing 10% FBS. After 24 hours, cells
were washed three times with media to remove TMZ and incubated for an additional 48
hours. Cytotoxicity of TMZ was determined by MTT assay after a total of 72 hours. For
the MTT assay, Thiazolyl Blue Tetrazolium Bromide (TBTB) was dissolved in PBS at 2
mg/mL and added to media on cells for a final concentration of 1 mg/ml. After a 4-hour
incubation at 37°C, the media containing TBTB was aspirated from the wells, and 500
µL of DMSO was added to each well to dissolve the formazan crystals. A Biotek Synergy
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plate reader (Winooski, VT) was used to measure absorbance at 540 nm. Cell viability
was normalized to untreated cells and determined by using the following equation:
Cell viability (%) = (Absorbance540(sample)/Absorbance540(control)) x 100%.

4.1.4 Preparation of TMZ-loaded Peptide Hydrogels
To prepare the peptide hydrogels, AE12K4, AE8K8, and AE4K12 peptides were
dissolved in a solution of 90% ethanol and 10% Milli-Q water at concentrations of 0.05
mg/mL, 0.1 mg/mL, and 0.5 mg/mL. TMZ was dissolved in Milli-Q water and combined
with each peptide solution for a final TMZ concentration of 200 µM. The final solution
was dehydrated to form a transparent drug-loaded film. The film was washed 3 times
with Milli-Q water to remove any unloaded or residual TMZ. Milli-Q water was then
added to rehydrate the film and allowed to shake for 2 hours. The amount of TMZ loaded
was determined by high-performance liquid chromatography (HPLC).

4.1.5 Characterization of Peptide Hydrogels
Zeta Potential and Dynamic Light Scattering
To determine the surface charge (zeta potential) and particle size of the peptide
hydrogel assemblies, laser doppler velocimetry combined with phase analysis light
scattering (M3-PALS) and dynamic light scattering, respectively, was conducted on the
peptide hydrogels prepared at a concentration of 0.05 mg/mL using a Zetasizer Nano ZS
(Malvern Instruments, Malvern, UK). The temperature of the Zetasizer was maintained at
25°C. The intensity of scattered light due to the complexes was collected at an angle of
173°, a refractive index of 1.6, and an absorbance value of 3.27. Three measurements
were tested to generate an intensity-based size distribution plot.
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CD Measurement
The peptide hydrogels were prepared at a concentration of 0.05 mg/mL and a
CD spectrum between 190 nm and 300 nm was recorded on a Jasco J-810 CD
Spectropolarimeter (Jasco, Inc., Easton, MD) at 20°C. All spectra were corrected by
subtracting the baseline and the data was expressed as the mean residue of ellipticity,
which was given in units of degrees per cm2/dmol. Predicted percentages of 𝛼-helices
and β-sheets were determined using CAPITO,61 a web server-based analysis and
plotting tool for CD data.

4.1.6 Determination of TMZ Loading in Peptide Hydrogels
The amount of TMZ loaded into each rehydrated peptide hydrogel was
determined using an HPLC system consisting of a Waters Model 2707 Autosampler
connected to a 1515 Isocratic HPLC Pump (Waters, Inc., Milford, MA). Samples were
injected onto the reverse phase Zorbax Rx-C18 column (4.6 x 250 mm, 5 µm). The
absorbance detector was set at 316 nm. The mobile phase consisted of 0.1% aqueous
acetic acid in Milli-Q water and methanol (90:10, v/v) and was delivered at 1.0 mL/min.
The amount of drug loading was determined by comparison to the given temozolomide
concentration (0.03 mg/mL).

4.1.7 Release of TMZ from Peptide Hydrogels in vitro
0.05 mg/mL of AE8K8 and AE4K12 peptide hydrogels, and 0.5 mg/mL of
AE12K4 peptide hydrogel was prepared as previously described in section 4.1.4. Instead
of TMZ, phenol red was loaded into the peptide hydrogels at a final concentration of 200
µM. To study release kinetics, the phenol red-loaded peptide hydrogels were placed into
a 96-well plate and incubated at 37°C. The absorbance of the phenol red was measured
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using a Biotek Synergy plate reader at 443 nm. The absorbance of each sample was
measured at 0, 1, 2, 4, 8, 12, 24, 48, 72, 96, and 120 hours. The amount of phenol red
released from the peptide hydrogel was calculated by comparison to the absorbance
value taken at the initial time point. The percentage of phenol remaining was determined
by using the equation below:
Amount Remaining (%) = (Absorbance443(Time X)/Absorbance443(Time 0)) x 100%.

4.1.8 Cytotoxicity of TMZ-Loaded Peptide Hydrogels
To analyze the anticancer activity of the TMZ-loaded peptide hydrogels, a
cytotoxicity study was performed. LN-18 (1X105) cells were cultured in 24-well plates
and allowed to attach overnight. AE12K4, AE8K8, and AE4K12 peptide hydrogels were
formed at the concentration that exhibited the highest TMZ loading for each peptide. The
TMZ-loaded peptide hydrogels were incubated with LN-18 cells at 200 µM for 72 hours
in media containing 10% FBS. Cells were treated with TMZ alone, unloaded peptide
hydrogel, or left untreated as controls. Cytotoxicity of TMZ was determined by MTT
assay after the 72-hour incubation period and cell viability was calculated as previously
described in section 4.1.3.

4.1.9 Statistical Analysis
Quantitative data were presented as mean ± SEM or standard deviation of three
independent experiments. Statistical analysis was performed using either Student’s t-test
or one-way ANOVA, where *P<0.05, **P<0.01. ***P<0.001, ****P<0.0001. A value of
P<0.05 was considered statistically significant.
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4.2 RESULTS
4.2.1 Peptide design and structure of peptide hydrogels
Three different compositions of self-assembling peptides were designed, each 16
amino acids in length, consisting of Alanine (A) as the hydrophobic domain, Glutamic
acid (E) as the hydrophilic/acidic domain, and Lysine (K) as the hydrophilic/basic domain
(Fig. 4.1). The peptides were synthesized and designed with alternating hydrophobic
and hydrophilic amino acids to promote self-assembly into a hydrogel when water is
introduced. The rationale for this design is that TMZ will load into the hydrophobic core
and maintain stability due to the acidic amino acid residues (Fig. 4.2). As the hydrogel
degrades, the basic amino acids will convert TMZ into its active form.
(A)

(B)

(C)

Figure 4.1. Peptide design and structure of peptide. AE12K4 (A), AE8K8 (B), and AE4K12 (C) peptides
were designed using peptide sequences consisting of alanine, glutamic acid, and lysine.
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Figure 4.2. Schematic of TMZ loading into peptide hydrogel. Alternating hydrophobic and hydrophilic
amino acids were used to promote self-assembly of a hydrogel. TMZ will load into the hydrophobic portion
and maintain stability due to the acidic amino acid residues. As the hydrogel degrades, the basic amino acids
will convert TMZ into its active form.

4.2.2 Cytotoxicity of TMZ versus pH
TMZ begins to convert to its active form, MTIC, at neutral pH; however, previous
studies have demonstrated that TMZ only fully converts to MTIC at a more basic pH
(>7.5).5 Though this has been shown, the effectiveness of TMZ when dissolved in
different pH environments has not been previously reported in the literature. Therefore,
to determine whether the anticancer activity of TMZ is pH dependent, a cytotoxicity study
was performed on human glioblastoma cells with TMZ dissolved in basic, neutral, and
acidic pH environments. The results showed that TMZ exhibited slight anticancer activity
at a pH of 2.5, but as the pH was increased, the anticancer activity of TMZ was
significantly enhanced in both LN-18 (Fig. 4.3A) and T98G (Fig. 4.3B) human
glioblastoma cell lines. Viability of cells treated with neutral TMZ was 56% and 83% in
LN-18 and T98G cells, respectively. Viability decreased by at least 25% when cells
were treated with basic TMZ compared to neutral TMZ, with viabilities of 30% and 58%
in LN-18 and T98G cells, respectively. These results demonstrate that the effectiveness
of TMZ is pH dependent and TMZ has the largest anticancer activity when dissolved in a
basic pH environment. These results validate the potential utility of basic pH amino acids
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residues in the design of the peptide hydrogels to increase the anticancer activity of
TMZ.
(A)

****
***

(B)

***
**

Figure 4.3. pH-dependent cytotoxicity of TMZ in LN-18 and T98G cells. Cell viability of (A) LN-18 and
(B) T98G human glioblastoma cells 72 hours after treatment with TMZ dissolved in water at a pH of 2.5,
7.5, and 12. Data are mean ± SEM of three independent experiments performed in triplicate, where
**P<0.01 and ***P<0.001 compared to untreated cells (control) which were considered 100% viable.

4.2.3 Characterization of Peptide Hydrogels
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After formulating AE4K12, AE8K8, and AE12K4 peptide hydrogels, we
characterized the particle size, zeta potential, and secondary structures of each peptide
hydrogel. Circular dichroism (CD) spectroscopy was used to measure the secondary
structure of each peptide design. The AE12K4 peptide hydrogel displayed a typical 𝛼helical spectra with negative peaks at 208 nm and 222 nm (Fig. 4.4A). The AE8K8
peptide hydrogel exhibited a β-sheet peak at 215 nm as well as an 𝛼-helix peak at 208
nm (Fig. 4.4B). CD analysis of AE4K12 peptide hydrogels revealed a standard β-sheet
structure with a negative peak at 215 nm (Fig 4.4C).
A)

B)

C)

Figure 4.4. Circular Dichroism (CD) analysis of the secondary structure of peptide hydrogels. CD
examination of the secondary structure of (A) AE12K4, (B) AE8K8 and (C) AE4K12 peptide hydrogels. (D)
Predicted proportions of secondary structures based on wavelength and mean residue ellipticity values taken
from CD results.
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The particle size and zeta potential of each peptide design was tested by DLS
and M3-PALS, respectively, at a concentration of 0.05 mg/mL. The mean particle sizes
determined using the Zetasizer ZS were 189.4 nm, 186.3 nm, and 248.3 nm for AE12K4,
AE8K8, and AE4K12 unloaded peptide hydrogels, respectively (Fig. 4.5A-C). The zeta
potential, an indicator of surface charge and stability, increased with the increasing
addition of lysine residues due to the positive charge of the lysine amino acid. The mean
zeta potentials were -10.6mV, -4.54mV, and 9.56mV for AE12K4, AE8K8, and AE4K12
peptide hydrogels, respectively (Fig. 4.5D).
(A)

(C)

(B)

(D)

Figure 4.5. Size and zeta potential of peptide hydrogels. Particle size distribution of (A) AE12K4, (B) AE8K8,
and (C) AE4K12 unloaded peptides hydrogels and (D) zeta potential were characterized using dynamic light
scattering. Data in table (D) are reported as mean ± standard deviation of peptide hydrogels analyzed in
triplicate.
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4.2.4 TMZ is efficiently loaded into peptide hydrogels
To assess whether TMZ could be loaded into AE4K12, AE8K8, and AE12K4
peptide hydrogels, we determined the amount of TMZ in drug-loaded peptide hydrogels
using HPLC. Drug loading ability of each peptide hydrogel composition was examined at
multiple concentrations, including 0.05, 0.1, and 0.5 mg/mL. TMZ was dissolved and
loaded into each formulation at a final concentration of 200 µM. The drug loading
efficiency was calculated for each peptide hydrogel. The maximum drug loading
efficiency for each peptide hydrogel was at least 85%, shown in figure 4.6. Based on
these findings, we selected the peptide concentration with the highest TMZ loading for
each peptide composition for further experimentation.

Figure 4.6. TMZ drug loading efficiency in peptide hydrogels. The amount of TMZ loaded for each peptide
hydrogel composition was determined at peptide concentrations of 0.05, 0.1, and 0.5 mg/mL
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4.2.5 Release Profiles of TMZ-Loaded Peptide Hydrogels
To examine the effect that peptide composition has on drug release, phenol red,
a pH indicator and dye, was loaded into each peptide hydrogel. The color change or
absorbance of phenol red from each peptide hydrogel was determined over time. The
results in figure 8A showed the AE12K4 peptide exhibited the slowest release, the
AE8K8 released faster, and the peptide with the fastest release was the AE4K12
peptide. Phenol red exhibits a color change from yellow to red as pH increases. To
confirm the change in pH and rate of degradation, images of each peptide hydrogel
containing phenol red were taken (Fig 4.7B). The well containing the AE4K12 peptide
hydrogel shows a faster color change or release of the phenol red dye. The AE12K4 and
AE8K8 peptide hydrogels start to exhibit a noticeable color change at day 3. This color
change confirms the phenol red absorbance measured over time represented in Figure
4.7A.
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(A)

(B)

Figure 4.7. Release of phenol red from peptide hydrogels. (A) Graph showing absorbance of phenol red as
a function of time. (B) Images taken during experiment, with the color intensity increasing as a result of phenol
red pH change.

4.2.6 Effect of TMZ-Loaded Peptide Hydrogels on Glioblastoma Cells in vitro
To evaluate the therapeutic potential of TMZ-loaded peptide hydrogels,
cytotoxicity of the drug-loaded hydrogels was determined using LN-18 cells at each
peptide composition. Cells were treated with TMZ alone, unloaded peptide hydrogel, or
TMZ-loaded peptide hydrogels at a TMZ concentration of 200 µM. The amount of TMZ
alone delivered onto cells was based on the highest amount of TMZ loaded into each
peptide (Fig 4.8). The percent viability of the LN-18 cells treated with TMZ alone was
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69% at the TMZ concentration of 200 µM. The percent viabilities of the LN-18 cells
treated with the peptide hydrogels were 72%, 54%, and 44% for AE12K4, AE8K8, and
AE4K12, respectively. These results were compared to the cytotoxicity of TMZ delivered
alone. The cytotoxicity of TMZ delivered by the AE8K8 and AE4K12 peptide hydrogels
were found to be statistically significant compared to delivery of TMZ alone. Overall,
these results demonstrate that each peptide design has either similar efficacy or is more
effective in delivering TMZ into glioblastoma cells than TMZ alone.

***

**

Figure 4.8. Peptide hydrogels enhance the anticancer effect of TMZ in vitro. Quantitative analysis of LN-18 cell
viability via MTT assay following 72-hour incubation with TMZ loaded into AE12K4 peptide, AE8K8 peptide,
and AE4K12. Data are mean ± SEM of three independent experiments performed in triplicate, where **P<0.01
compared to TMZ treated cells.
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CHAPTER 5

DISCUSSION

In this study, we developed a delivery strategy for TMZ that uses amino acids to
form a hydrogel that encapsulates the prodrug and converts it into its active form. We
demonstrated the efficacy of the delivery system, confirming the potential of the TMZloaded peptide hydrogel as a new treatment strategy for glioblastoma, which increases
TMZ anticancer activity and may ultimately result in improved therapeutic efficacy.
Furthermore, the peptide hydrogel may allow for delivery of smaller dosages of TMZ,
which could decrease the toxic side effects of the drug.

Our results demonstrate the pH-dependent efficacy of TMZ in human
glioblastoma cells. This is particularly significant because though the pH driven
activation of TMZ has been shown,5 to our knowledge, the pH-dependent efficacy of the
drug on cancer cells has not been previously reported. Our results confirm that the
anticancer activity of TMZ is significantly greater when the drug is dissolved at basic pH
compared to neutral or acidic pH. This result aligns with studies demonstrating that TMZ
is only partially activated at neutral pH and has implications on the current clinical
strategy for delivery of TMZ.5 Oral delivery of TMZ relies on the conversion of the drug to
its active form at physiological pH once it reaches the bloodstream.62 The low
therapeutic efficacy of TMZ seen clinically in glioblastoma patients7 may in part be due to
the incomplete conversion of TMZ at physiological pH, resulting in limited anticancer
activity, as we have demonstrated in vitro. This experiment validated the potential of our
peptide hydrogel design including acidic and basic amino acids to improve the efficacy of
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TMZ. Acidic amino acids are included in the interior to provide stability since TMZ is
stable as a prodrug at acidic pH,62 which we also confirmed in vitro; TMZ dissolved in an
acidic environment was only slightly cytotoxic to glioblastoma cells. Basic amino acids
are included on one end of the peptide to mediate the conversion of TMZ to its active
form upon release from the hydrogel.

After the peptides were designed and synthesized, we conducted
characterization studies to evaluate the size, stability, and secondary structures of each
peptide hydrogel. The diameter of all the peptide hydrogels ranged from 150-300 nm.
Nanoparticles are ideal for systemic delivery of cancer therapeutics due to their small
size;63 therefore, the TMZ-loaded peptide hydrogels may have the potential for
intravenous delivery. The stability and potential cytotoxicity can be verified by the zeta
potential measurements. Values between +30mV to -30mV are considered to be less
stable and are more likely to coagulate or gel. The zeta potential of the peptide designs
ranged from -10mV to +10mV, indicating more slightly charged or neutral hydrogels.
Circular dichroism (CD) spectroscopy was used to understand the secondary structures
of the peptides. The AE4K12 peptide hydrogel displayed a typical β -sheet structure with
a negative peak at 215 nm. The AE8K8 peptide hydrogel displayed a β-sheet peak at
215 nm, but also an α-helix peak at 208 nm. AE12K4 peptide hydrogels displayed a
typical 𝛼-helical structure with a negative peak at 208 nm and 222 nm. The formation of
𝛼-helices and/or random coils are due to the number of repeated patterns of
hydrophobic and charged amino acid residues. The presence of lysine amino acids can
explain the formation of more β-sheet structures, which is most likely due to better
crosslinking of the peptide. We found it difficult to achieve a high count number when
using the zeta sizer. This could be due to the low peptide concentration chosen or the
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peptide index of refraction being too similar to water. Further studies using scanning
electron microscopy (SEM) need to be conducted to further confirm the sizing of each
peptide hydrogel.

Following characterization, we demonstrated that the peptide hydrogels
efficiently loaded TMZ, with an average loading efficiency of at least 85%. The AE12K4
peptide hydrogel was found to load the greatest amount of TMZ and also exhibited an
increase in loading capacity with increasing peptide concentration. The AE8K8 and
AE4K12 peptide hydrogels required higher peptide concentrations than the
concentrations tested to increase loading, likely due to smaller hydrophobic regions
compared to the AE12K4 peptide. These results demonstrate that hydrophobic drug
loading capacity increases with increasing number of alanine amino acids. Future work
should include optimizing TMZ loading into each peptide hydrogel, as well as attempting
to load other alkylating prodrugs to demonstrate the versatility of the delivery system.

The release profiles of each peptide hydrogel loaded with phenol red dye was
then examined. We found that the AE12K4 peptide had the slowest rate of pH change
over time, and the release rate did in fact increase with the reduction of alanine amino
acids. We hypothesized that including alanine residues in the peptide design would allow
for an increase in release rate, due to the hydrophobic nature of alanine. Our results
demonstrate the tunability of the peptide hydrogels, or the ability to adjust the rate of
drug release from the delivery vehicle.

To determine the efficacy of TMZ-loaded peptide hydrogels, cytotoxicity studies
were performed using LN-18 human glioblastoma cells. We found TMZ-loaded AE12K4
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peptide hydrogels exhibited anticancer activity similar to delivering TMZ alone. The TMZloaded AE8K8 and AE4K12 peptide hydrogels increased cytotoxicity in LN-18 cells by
approximately 15% and 25% respectively, compared to TMZ alone. We hypothesized
that including lysine resides in the peptide design would enable conversion of TMZ into
its active form. Our results demonstrate that the efficacy of TMZ increases with the
number of basic amino acid residues included in the peptide design. Efficacy could also
be affected by slower release of TMZ from AE12K4 and AE8K8 peptide hydrogels
caused by the additional alanine amino acids. Future studies will include the T98G
human glioblastoma cell line to evaluate the effectiveness of the TMZ-loaded peptide
hydrogel on a more resistant cell line. A TUNEL assay that quantifies the apoptotic
activity of cells, may also be attempted for future studies. Due to the mechanism in
which TMZ causes cell death, the TUNEL assay may be a more suitable method in
confirming the efficacy of the delivery system.
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CHAPTER 6

CONCLUSION

In conclusion, our in vitro results confirmed that TMZ is more effective in a basic
pH environment, likely due to increased conversion of the drug to its active form,
validating the design of our peptide hydrogels. We demonstrated that AE12K4, AE8K8,
and AE4K12 peptide hydrogels efficiently load TMZ and their release profiles can be
adjusted based on peptide composition or the hydrophobic to hydrophilic amino acid
ratio. Further, the AE8K8 and AE4K12 TMZ-loaded peptide hydrogels increased
anticancer activity in human glioblastoma cells compared to delivery of TMZ alone. The
physical and biological results demonstrate the therapeutic potential of the TMZ-loaded
peptide hydrogels for local drug delivery in treating GBM. However, further studies using
in vivo models of GBM are necessary to further confirm the clinical potential of the TMZloaded peptide hydrogels.
Peptide-based drug delivery shows great promise in the treatment of cancer.
Drug delivery using peptides can assist in overcoming the blood brain barrier (BBB), and
in increasing the conversion of pH-activated prodrugs to their active parent drug. The
peptide hydrogels in this study show potential for becoming a new treatment for GBM.
With further studies, we aim to optimize this vehicle for delivery of not only TMZ, but
other anticancer prodrugs. In doing this, we hope to advance therapeutic strategies
using carriers that enhance drug activity and ultimately increase GBM patient survival
rates and reduce disease progression.
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